Abstract
We carried out the current meta-analysis of relevant cohort studies in an attempt to investigate the relationships between vascular endothelial growth factor (VEGF) protein expression and lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) among Asians. A range of electronic databases were searched, including Web of Science (1945 ∼ 2013), the Cochrane Library Database (Issue 12, 2013), MEDLINE (1966 ∼ 2013), EMBASE (1980 ∼ 2013), CINAHL (1982 ∼ 2013), and Chinese Biomedical Database (CBM) (1982 ∼ 2013) with cross-referencing without language restrictions. Meta-analysis was conducted using the STATA 12.0 software. Crude odds ratio (OR) with their 95 % confidence interval (95 %CI) was calculated. Twelve clinical cohort studies with a total of 1,045 PTC patients were included in our meta-analysis, The results of our meta-analysis revealed that patients with VEGF-positive tumors had a 3.02-fold higher risk of LN metastasis than that of patients with VEGF-negative tumors (OR = 3.02, 95 %CI = 2.05 ∼ 4.43, P < 0.001). Furthermore, subgroup analysis by country suggested that VEGF-positive expression was associated with an increased risk of LN metastasis in PTC patients among Chinese populations (OR = 3.33, 95 %CI = 2.30 ∼ 4.83, P < 0.001), but not among Korean, Turkish, and Japanese populations (all P > 0.05). Our findings support the view that VEGF protein expression may be correlated with LN metastasis in PTC patients, especially among Chinese populations.
Similar content being viewed by others
References
LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011;24 Suppl 2:S1–9.
Mazzaferri EL, Doherty GM, Steward DL. The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. Thyroid. 2009;19(7):683–9.
Lukas J, Drabek J, Lukas D, Dusek L, Gatek J. The epidemiology of thyroid cancer in the Czech Republic in comparison with other countries. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157(3):266–75.
Swierniak M, Wojcicka A, Czetwertynska M, Stachlewska E, Maciag M, Wiechno W, et al. In-depth characterization of the microrna transcriptome in normal thyroid and papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(8):E1401–9.
Liao S, Song W, Liu Y, Deng S, Liang Y, Tang Z, et al. Familial multinodular goiter syndrome with papillary thyroid carcinomas: mutational analysis of the associated genes in 5 cases from 1 Chinese family. BMC Endocr Disord. 2013;13(1):48.
Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.
Wartofsky L. Increasing world incidence of thyroid cancer: increased detection or higher radiation exposure? Horm (Athens). 2010;9(2):103–8.
Kabat GC, Kim MY, Wactawski-Wende J, Lane D, Wassertheil-Smoller S, Rohan TE. Menstrual and reproductive factors, exogenous hormone use, and risk of thyroid carcinoma in postmenopausal women. Cancer Causes Control. 2012;23(12):2031–40.
Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88(4):271–7.
Erdem H, Gundogdu C, Sipal S. Correlation of E-cadherin, VEGF, Cox-2 expression to prognostic parameters in papillary thyroid carcinoma. Exp Mol Pathol. 2011;90(3):312–7.
Yasuoka H, Nakamura Y, Zuo H, Tang W, Takamura Y, Miyauchi A, et al. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol. 2005;18(8):1127–33.
Tian X, Cong M, Zhou W, Zhu J, Liu Q. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer. J Int Med Res. 2008;36(4):699–703.
Bates DO. Vascular endothelial growth factors and vascular permeability. Cardiovasc Res. 2010;87(2):262–71.
Poh CK, Shi Z, Lim TY, Neoh KG, Wang W. The effect of VEGF functionalization of titanium on endothelial cells in vitro. Biomaterials. 2010;31(7):1578–85.
Miller JW, Le Couter J, Strauss EC, Ferrara N. Vascular endothelial growth factor a in intraocular vascular disease. Ophthalmology. 2013;120(1):106–14.
Doi K, Noiri E, Fujita T. Role of vascular endothelial growth factor in kidney disease. Curr Vasc Pharmacol. 2010;8(1):122–8.
Hsueh C, Lin JD, Wu IC, Chao TC, Yu JS, Liou MJ, et al. Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma. J Surg Oncol. 2011;103(5):395–9.
Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011;17(7):347–62.
Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2010;21(1):21–6.
Salajegheh A, Pakneshan S, Rahman A, Dolan-Evans E, Zhang S, Kwong E, et al. Co-regulatory potential of vascular endothelial growth factor-a and vascular endothelial growth factor-c in thyroid carcinoma. Hum Pathol. 2013;44(10):2204–12.
Kamat A, Rajoria S, George A, Suriano R, Shanmugam A, Megwalu U, et al. Estrogen-mediated angiogenesis in thyroid tumor microenvironment is mediated through VEGF signaling pathways. Arch Otolaryngol Head Neck Surg. 2011;137(11):1146–53.
Pasquali D, Santoro A, Bufo P, Conzo G, Deery WJ, Renzullo A, et al. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation. Thyroid. 2011;21(4):391–9.
de Araujo-Filho VJ, Alves VA, de Castro IV, Lourenco SV, Cernea CR, Brandao LG, et al. Vascular endothelial growth factor expression in invasive papillary thyroid carcinoma. Thyroid. 2009;19(11):1233–7.
Yu XM, Lo CY, Lam AK, Lang BH, Leung P, Luk JM. The potential clinical relevance of serum vascular endothelial growth factor (VEGF) and VEGF-C in recurrent papillary thyroid carcinoma. Surgery. 2008;144(6):934–40. discussion 40-1.
Kim BH, Lee CH, Kim SJ, Jeon YK, Kim SS, Kim YK, et al. Clinicopathologic characteristics of synchronous primary thyroid cancer detected by initial staging (18)F-FDG PET-CT examination in patients with underlying malignancy. Thyroid. 2013;23(11):1431–6.
Li J, Teng L, Jiang H. Relationship between preoperative serum TSH levels and expression of VEGF in papillary thyroid carcinoma. Asia Pac J Clin Oncol. 2013;40(5):455–8.
Stang A. Critical evaluation of the newcastle-ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
Zintzaras E, Ioannidis JP. Hegesma: genome search meta-analysis and heterogeneity testing. Bioinformatics. 2005;21(18):3672–3.
Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.
Miao AL, Wan MZ, Cheng L. Expression of Cox-2 and VEGF-C in papillary thyroid carcinoma and their relationship to cervical lymph metastases. J Clin Otorhinolaryngol Head Neck Surg. 2009;23(19):881–3.
Lee SH, Lee SJ, Jin SM, Lee NH, Kim DH, Chae SW, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5(3):150–5.
Jiang HG, Gao M, Tang WP, Li FH, Cai QZ. Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma. Chin J Cancer. 2005;24(9):1136–9.
Luo HJ, Li JP, Yang TF, Wang JD. Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2009;12:531–4.
Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM. Increased expression of vascular endothelial growth factor c in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin Cancer Res. 2005;11(22):8063–9.
Wang T, Jiang CX, Li Y, Liu X. Pathologic study of expression and significance of matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, vascular endothelial growth factor and transforming growth factor beta-1 in papillary carcinoma and follicular carcinoma of thyroid. Chin J Pathol. 2009;38(12):824–8.
Wang YQ, Hua QQ. Clinical significance of HIF-1 alpha, VEGF and VEGF-C expression in papillary thyroid carcinoma. J Clin Otorhinolaryngol Head Neck Surg. 2007;21(5):204–6,8.
Tanaka K, Kurebayashi J, Sonoo H, Otsuki T, Yamamoto Y, Ohkubo S, et al. Expression of vascular endothelial growth factor family messenger rna in diseased thyroid tissues. Surg Today. 2002;32(9):761–8.
Karpanen T, Egeblad M, Karkkainen MJ, Kubo H, Yla-Herttuala S, Jaattela M, et al. Vascular endothelial growth factor c promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61(5):1786–90.
Freeman R, Girsh J, Jou AF, Ho JA, Hug T, Dernedde J, et al. Optical aptasensors for the analysis of the vascular endothelial growth factor (VEGF). Anal Chem. 2012;84(14):6192–8.
Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009;15(3):232–9.
Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, et al. The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci U S A. 2009;106(32):13505–10.
Acknowledgments
We would like to acknowledge the reviewers for their helpful comments on this paper.
Conflicts of interest
None
Author information
Authors and Affiliations
Corresponding author
Additional information
The Publisher and Editor retract this article in accordance with the recommendations of the Committee on Publication Ethics (COPE). After a thorough investigation we have strong reason to believe that the peer review process was compromised.
About this article
Cite this article
Chang, DF., Xu, ZQ. & Sun, B. RETRACTED ARTICLE: Relationship between VEGF protein expression and lymph node metastasis in papillary thyroid carcinoma among Asians: a meta-analysis. Tumor Biol. 35, 5511–5518 (2014). https://doi.org/10.1007/s13277-014-1725-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13277-014-1725-3